by Gary S. Morrow | Dec 11, 2019 | Charts, Commentary
EMR spent the month of November consolidating after its powerful post earnings surge on Nov. 4th. The stock has perked up this week. The post earnings consolidation appears to have ended with an upside breakout. More upside looks likely. At time of publication we are...
by Gary S. Morrow | Dec 9, 2019 | Charts, Commentary
FCX is piercing as key overhead trendline as the new week begins. FCX is heading for its best close since late April. The stock is up over 4% as it begins to put some distance on the November peak while extending the post earnings(10/23) gain to 20%. A solid support...
by Gary S. Morrow | Dec 5, 2019 | Charts, Commentary
Our flagship LifePro Tactical Opportunity Strategy rose 9.43% in the month of November, bringing the total advance in 2019 to +39.43%, net of fees. These results strongly outpaced the S&P 500, which rose +3.40% in November and +25.30% in 2019, as of November 30th....
by Gary S. Morrow | Dec 4, 2019 | Charts, Commentary
DE was hit hard after earnings(11/27). By yesterday’s low the stock was down 10% from the November highs. The 200D is holding up well after four days of heavy selling pressure.
by Gary S. Morrow | Dec 3, 2019 | Charts, Commentary
Fascinating data from bespokepremium.com. Since 1993 when $SPY began trading, had you bought SPY at the close every day and sold at the next open (after hours), you’d be up 722%. Had you done the opposite and bought every open and sold same day’s close...
by Gary S. Morrow | Dec 2, 2019 | Charts, Commentary
The IBB(iShares Nasdaq Biotechnology Fund) has entered overbought territory. The IBB is showing signs of exhaustion as the new month begins. The index has had a huge rally off the October lows. At last week’s high the IBB had gained over 25% over the previous...
